Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
CurisApr 30 00:00 ET
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Curis, Inc. (NASDAQ:CRIS) shares have continued their recent momentum with a 36% gain in the last month alone. The bad news is that even after the stocks recovery in the last 30 days, shareholders
Simply Wall StApr 25 08:52 ET
Changes in Hong Kong stocks | China Tongshi (01763) rose more than 4%, China Nuclear Qualcomm officially has the capacity to produce and supply Nuclides such as Wancuri GMP grade N-177
The Zhitong Finance App learned that China's Tongbo (01763) rose by more than 4%. As of press release, it had risen 3.85% to HK$10.26, with a turnover of HK$1,228,800. According to the news, the China Communications Agency announced that recently, the first domestic production line with an annual output of Wanjuli grade Carrier-free Zi-177 GMP and an annual production capacity of 1,000 germanium 68Ge-68Ga generators was fully completed and put into operation, marking the actual realization of large-scale commercialization of the two GMP-grade GMP-grade GE-177 and Gallium-68 medical nuclides. The smooth commissioning of the production line will effectively mitigate domestic supply shortages of Zn-177 and Gallium-68
Zhitong FinanceApr 23 02:49 ET
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indica
BenzingaApr 12 08:34 ET
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
CurisApr 5 00:00 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersCandel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. TC BioPharm (Holdin
BenzingaApr 4 12:31 ET
Curis to Present at Upcoming Healthcare Conferences in April
LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
CurisApr 4 00:00 ET
Curis (CRIS) Gets a Buy From Truist Financial
TipRanksMar 8 07:15 ET
Curis Inc. Is Worried About This – Should You Be Worried Too?
TipRanksFeb 10 01:00 ET
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Adv
BenzingaFeb 9 08:11 ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Curis (CRIS)
TipRanksFeb 9 08:10 ET
Curis Is Maintained at Buy by HC Wainwright & Co.
Curis Is Maintained at Buy by HC Wainwright & Co.
Dow JonesFeb 9 06:18 ET
Express News | HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $26
Moomoo 24/7Feb 9 06:07 ET
Curis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/09/2024 165.04% HC Wainwright & Co. $51 → $26 Maintains Buy 11/17/2023 165.04% Truist Securities → $26
BenzingaFeb 9 06:06 ET
Curis Reports Positive Emavusertib Trial Results, Extends Cash Runway
InvestingFeb 8 22:58 ET
Earnings Call: Curis Reports Q4 Losses, Progresses in Oncology Trials
InvestingFeb 8 21:20 ET
Express News | Curis Said May Offer, Sell Shares Of Common Stock From Time To Time In One Or More Offerings Of Up To $300M In Aggregate Offering Price
Moomoo 24/7Feb 8 16:35 ET
Earnings Call Summary | Curis(CRIS.US) Q4 2023 Earnings Conference
The following is a summary of the Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript:Financial Performance:Curis reported a net loss of $11.7 million or $2.03 per share for Q4 2023, slightly higher t
moomoo AIFeb 8 15:59 ET · Conference Call
Curis Inc Q4 Sales Decline
RTTNewsFeb 8 08:20 ET
Curis: As of Dec 31, Cash, Cash Equivalents and Investments Totaled $56.3M >CRIS
Curis: As of Dec 31, Cash, Cash Equivalents and Investments Totaled $56.3M >CRIS
Dow JonesFeb 8 08:03 ET
No Data
No Data